WBI Pwr Ftr Hg Div

UPS Subsidiary and The Bouqs Co. Collaborate to Offer Same-Day Holiday Flower Delivery

AWBC and Verizon Partner to Enhance Entrepreneurial Education and Digital Readiness

BioNTech SE and Bristol Myers Squibb Report Positive Mid-Stage II Results for Pumitamig in Advanced Triple-Negative Breast Cancer

Pfizer and WuXi Biologics Reach Exclusive Cooperation and Licensing Agreement

Pfizer Partners with Yao Pharmaceutical for Chronic Weight Management Drug

Fosun Pharma's Subsidiary Signs Global License Agreement with Pfizer for GLP-1R Agonist

Bristol Myers Squibb to present new lymphoma treatment data at the 67th ASH annual meeting

1832 Asset Management Sells Significant Stake in Altria

Eli Lilly and Pfizer Successfully Included in China's Private Health Insurance Directory

Pfizer's HYMPAVZI Significantly Reduces Bleeding Events in Hemophilia Patients

Jefferies Maintains Buy Rating for BMS with a Price Target of $68

Edison International Obtains Hydro Power Project Concessions in Argentina

Panagora Asset Management Inc. Significantly Reduced Holdings in Verizon Communications

Breyanzi Approved by FDA for Treatment of Marginal Zone Lymphoma

Atlantic Investment Management Fully Exits Eastman Chemical Holdings

EDF Plans to Sell Minority Stake in Edison to Support Green Investments

XTX Topco Ltd significantly reduced holdings in UPS

Edison International Launches Over 500MW Renewable Energy New Projects

Terray Therapeutics Reaches Milestone in Drug Discovery Using EMMI Platform

Bristol Myers Squibb to recruit more participants for Cobenfy's late-stage trial

Aimei Health Tech

Oriental Culture

Netcapital

Lion

JX Luxventure

ALPHAVEST ACQUISITION CORP ORD USD0.0001(S/R 22/01/26)

Designer Brands

Horizon Space Acquisition I

Cypherpunk Tech

Alexander & Baldwin

Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for long-term investors.

Pfizer

Down 50%, should you buy the dip on Pfizer?

Eastman Chemical Co. stock rose 1.32% to $61.21 on Tuesday, despite underperforming compared to competitors like Exxon Mobil, Dow Inc., and Corteva Inc. The stock remains 41.04% below its 52-week high. Trading volume was slightly below the 50-day average. The S&P 500 and Dow Jones both fell during the session.

Dow Jones

Eastman Chemical

Eastman Chemical Co. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

Edison International's stock rose 1.07% to $56.63, outperforming competitors during a weak market session. The S&P 500 fell 0.09% and the Dow Jones dropped 0.38%. Edison is 31.83% below its 52-week high of $83.07. Competitors NextEra Energy fell 1.13%, Southern Co. fell 0.08%, and Dominion Energy rose 0.03%. Trading volume was below average.

Edison

Edison International Stock Outperforms Competitors On Strong Trading Day

SPOT

UBER

WELL

Newmont(NEM) rose 5.72%, with a trading turnover 805.2 Million USD, and a year-to-date rose 157.1%. AppLovin(APP) rose 5.05%, with a trading turnover 2.8 Billion USD, and a year-to-date rose 123.8%. JPMorgan Chase(JPM) fell 4.66%, with a trading turnover 5.4 Billion USD, and a year-to-date rose 28%. Uber Tech(UBER) fell 3.78%, with a trading turnover 1.5 Billion USD, and a year-to-date rose 47.7%.

Top Gainers & Losers

Newmont

AppLovin

Blackstone

Spotify

JPMorgan Chase

Uber Tech

Boeing

Verizon

Welltower Op

Top 5 US Stock Gainers/Losers (>100B) (12.9)

Bristol Myers Squibb Co. stock fell 1.97% to $50.65 on Tuesday, underperforming compared to competitors like Johnson & Johnson, Pfizer, and Abbott Laboratories. This marked the second consecutive day of losses for BMY, closing 20.02% short of its 52-week high. Trading volume was 4.1 million below its 50-day average. The S&P 500 and Dow Jones also experienced declines.

Bristol Myers Squibb

Bristol Myers Squibb Co. Stock Underperforms Tuesday When Compared To Competitors

Philip Morris International Inc. shares rose 1.40% to $150.37, outperforming competitors on a day when the S&P 500 and Dow Jones fell. This marks the second consecutive day of gains for the stock, which is 19.45% below its 52-week high. Trading volume was 2 million below the 50-day average. Competitors like Altria, Universal Corp., and Mativ Holdings also saw gains.

Altria

Phillip Morris

Philip Morris International Inc. Stock Outperforms Competitors On Strong Trading Day

Pfizer Strikes Licensing Deal For Chinese Company's Obesity Drug Candidate

marketscreener

Pfizer Strikes Licensing Deal For Chinese Company's Obesity Drug Candidate

MIRM

Health care stocks declined, with NYSE Health Care Index down 0.6%. Mirum Pharmaceuticals acquired Bluejay Therapeutics, expanding its pipeline. Pfizer signed a collaboration deal with YaoPharma. CVS Health raised its full-year outlook, expecting higher earnings in 2026. Teleflex sold units for $2.03 billion, boosting shares by 9.7%.

- Health care stocks experienced a decline, with the NYSE Health Care Index down 0.6% and the State Street Health Care Select Sector SPDR ETF decreasing 1%.  
- Mirum Pharmaceuticals acquired Bluejay Therapeutics to enhance its rare liver disease pipeline, while Pfizer entered a collaboration with YaoPharma for chronic weight management.  
- CVS Health raised its full-year outlook, and Teleflex announced the sale of several units for $2.03 billion, leading to a 9.7% increase in its shares.

fidelity

Mirum Pharmaceuticals

Teleflex

CVS Health

Sector Update: Health Care Stocks Softer Late Afternoon

American Oncology Network Inc. has appointed Dr. Robert J. McDonald as Radiology Medical Director. He will oversee radiology services in Naples, Fort Myers, and Macon, provide advanced radiotheranostic therapies, and lead the expansion of radiotheranostic services across the network. This appointment was announced on December 09, 2025, and the information is provided by Public Technologies using AI-generated content.

Reuters

American Oncology Network Appoints Dr. Robert J. McDonald as Radiology Medical Director

Health care stocks declined, with NYSE Health Care Index down 0.4%. Pfizer signed a deal with YaoPharma for weight management drug YP05002, shares down 0.9%. CVS Health raised its full-year outlook, shares up 2.9%. Teleflex sold units for $2.03 billion, shares up 11%.

- Health care stocks experienced a decline, with the NYSE Health Care Index down 0.4% and the State Street Health Care Select Sector SPDR ETF decreasing 0.5%.  
- Pfizer announced a global collaboration with YaoPharma for chronic weight management, resulting in a 0.9% drop in its shares, while CVS Health raised its full-year outlook, leading to a 2.9% increase in its stock.  
- Teleflex agreed to sell several units for $2.03 billion in cash, causing its shares to rise over 11%.

Sector Update: Health Care Stocks Lower in Afternoon Trading

BNTX

BioNTech, Bristol Myers Report Early Breast Cancer Tumor Response Data for Experimental Antibody Treatment

BioNTech SE

BioNTech, Bristol Myers Report Early Breast Cancer Tumor Response Data for Experimental Antibody Treatment

UPS, through its subsidiary Roadie, has partnered with The Bouqs Co. to offer same-day flower delivery in key markets like New York, Los Angeles, and Miami. This collaboration aims to meet increased demand during the holiday season, with a projected 44% rise in order volume in Q4. Roadie's network allows Bouqs to expand its same-day delivery offerings beyond physical stores.

UPS Partners with Bouqs to Enable Same-Day Flower Delivery in Key Markets